Taylor Wealth Management Partners - GLOBAL BLOOD THERAPEUTICS IN ownership

GLOBAL BLOOD THERAPEUTICS IN's ticker is GBT and the CUSIP is 37890U108. A total of 195 filers reported holding GLOBAL BLOOD THERAPEUTICS IN in Q2 2022. The put-call ratio across all filers is 0.79 and the average weighting 0.4%.

Quarter-by-quarter ownership
Taylor Wealth Management Partners ownership history of GLOBAL BLOOD THERAPEUTICS IN
ValueSharesWeighting
Q2 2022$892,000
-13.1%
27,917
-5.7%
0.51%
+22.2%
Q1 2022$1,026,000
+16.1%
29,615
-1.9%
0.42%
+33.4%
Q4 2021$884,000
-45.8%
30,187
-52.9%
0.31%
-46.6%
Q3 2021$1,632,000
-34.0%
64,051
-9.2%
0.58%
-33.2%
Q2 2021$2,471,000
-14.1%
70,570
-0.1%
0.87%
-17.0%
Q1 2021$2,878,000
+3.3%
70,637
+9.8%
1.05%
-2.0%
Q4 2020$2,786,000
-3.9%
64,321
+22.3%
1.07%
-19.4%
Q3 2020$2,900,000
+7.1%
52,597
+22.6%
1.33%
-3.4%
Q2 2020$2,709,000
+17.6%
42,917
-4.9%
1.38%
-2.6%
Q1 2020$2,304,000
-36.3%
45,105
-0.9%
1.41%
-15.2%
Q4 2019$3,618,000
+63.0%
45,516
-0.5%
1.67%
+60.6%
Q3 2019$2,219,000
-5.9%
45,726
+2.1%
1.04%
-5.7%
Q2 2019$2,357,000
-0.1%
44,801
+0.5%
1.10%
-6.3%
Q1 2019$2,360,000
+28.3%
44,584
-0.5%
1.18%
+10.7%
Q4 2018$1,839,000
+14.7%
44,788
+6.2%
1.06%
+55.6%
Q3 2018$1,603,000
-12.5%
42,183
+4.1%
0.68%
-16.3%
Q2 2018$1,832,000
-7.1%
40,541
-0.7%
0.82%
-14.1%
Q1 2018$1,971,000
+2.5%
40,816
-16.5%
0.95%
+16.2%
Q4 2017$1,923,000
+30.2%
48,865
+2.7%
0.82%
+24.0%
Q3 2017$1,477,00047,5650.66%
Other shareholders
GLOBAL BLOOD THERAPEUTICS IN shareholders Q2 2022
NameSharesValueWeighting ↓
Grace Capital 177,414$14,103,00011.50%
Fernwood Investment Management, LLC 258,012$20,509,0009.81%
Perceptive Advisors 5,865,726$466,266,0009.26%
ArchPoint Investors 186,756$14,845,0004.54%
STANSBERRY ASSET MANAGEMENT, LLC 115,638$9,192,0003.74%
Camber Capital Management LP 730,000$58,028,0002.95%
Profit Investment Management, LLC 46,873$3,726,0002.50%
Casdin Capital, LLC 300,000$23,847,0002.19%
SECTORAL ASSET MANAGEMENT INC 174,594$13,878,0002.07%
Corriente Advisors, LLC 40,000$3,180,0001.71%
View complete list of GLOBAL BLOOD THERAPEUTICS IN shareholders